New Treatments for HAE – by N.M. Johnson NM1 and M.A. Phillips, Virginia Tech Carilion School of Medicine, USA:
The past decade has been marked by the development of new treatment options for the management of HAE. Many international and national consensus guidelines exist, but none recommend speci c therapies, citing a lack of head-to-head trials. The decision to use prophylactic therapy requires weighing the patient’s disease burden with the bene ts and risks of therapy.
For those patients who do require preventative therapy, Cinryze (C1 esterase inhibitor) appears to be equally as effective as synthetic androgens, and neither is recommended above the other. Berinert (C1 esterase inhibitor), Ruconest (conestat alfa), Firazyr (icatibant), and Kalbitor (ecallantide) appear to be equally ef cacious, and the decision of which particular agent to use should depend on patient factors, including setting of administration and responsiveness to a particular agent during previous acute episodes. (Skin Therapy Lett., January 2018)